Voya Investment Management LLC Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Voya Investment Management LLC raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,548 shares of the biotechnology company's stock after purchasing an additional 1,581 shares during the quarter. Voya Investment Management LLC owned 0.09% of United Therapeutics worth $13,601,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. bought a new position in United Therapeutics in the 4th quarter worth about $25,000. Millstone Evans Group LLC bought a new position in United Therapeutics in the fourth quarter worth approximately $67,000. MassMutual Private Wealth & Trust FSB increased its holdings in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Natixis bought a new stake in United Therapeutics during the 4th quarter valued at $85,000. Finally, Anchor Investment Management LLC lifted its holdings in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after buying an additional 30 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In related news, Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $285.57, for a total value of $856,710.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at approximately $499,747.50. The trade was a 63.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 74,500 shares of company stock valued at $24,472,050 in the last ninety days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Down 1.7 %

Shares of NASDAQ:UTHR opened at $291.38 on Monday. United Therapeutics Co. has a 52-week low of $233.31 and a 52-week high of $417.82. The business has a 50-day moving average price of $308.67 and a 200-day moving average price of $346.42. The stock has a market cap of $13.09 billion, a price-to-earnings ratio of 12.80, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same quarter last year, the business posted $4.36 EPS. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on UTHR. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a report on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, JPMorgan Chase & Co. reduced their price target on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $390.17.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.